Analysts See $0.71 EPS for GlaxoSmithKline plc (ADR) (GSK)

July 17, 2017 - By test

 Analysts See $0.71 EPS for GlaxoSmithKline plc (ADR) (GSK)

Investors wait GlaxoSmithKline plc (ADR) (NYSE:GSK) to report on July, 26. its quarterly earnings Wall Street analysts expect $0.71 EPS, up $0.01 or 1.43 % from last year’s $0.7 same quarter earnings. This translates into $1.71B profit for GSK giving the stock a 14.90 P/E. This is assuming the current $0.71 EPS is accurate. GlaxoSmithKline plc (ADR)’s Wall Street analysts see 14.52 % EPS growth, taking into account the $0.62 EPS reproted in the previous quarter, It is down 4.26% since July 18, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Among 14 analysts covering GlaxoSmithKline (NYSE:GSK), 7 have Buy rating, 0 Sell and 7 Hold. Therefore 50% are positive. GlaxoSmithKline had 21 analyst reports since September 8, 2015 according to SRatingsIntel. Piperjaffray initiated the shares of GSK in report on Friday, September 23 with “Overweight” rating. On Thursday, July 14 the stock rating was upgraded by Jefferies to “Buy”. Bryan Garnier & Cie upgraded the stock to “Buy” rating in Wednesday, January 27 report. Argus Research maintained the shares of GSK in report on Monday, December 7 with “Buy” rating. The firm has “Neutral” rating given on Wednesday, July 5 by Citigroup. JP Morgan upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Monday, October 12 to “Neutral” rating. On Thursday, October 20 the stock rating was initiated by Investec with “Buy”. The firm has “Underperform” rating by BNP Paribas given on Wednesday, September 14. Berenberg upgraded the shares of GSK in report on Friday, May 26 to “Buy” rating. The firm has “Neutral” rating by BNP Paribas given on Tuesday, September 15.

GlaxoSmithKline plc is a global healthcare company. The company has market cap of $101.75 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 47.2 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Another recent and important GlaxoSmithKline plc (ADR) (NYSE:GSK) news was published by which published an article titled: “Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks” on July 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.